From challenges to opportunities, awareness to readiness, explore what Oncidium’s voices have to say about advancing Radiotheranostics Today.

Read Newsletter

 

In this issue:

 

  • “Don’t forget the child”: Dr. Helen Nadel on pediatric radiotheranostics. Interview by Tala Allahham & Dr. Cristiana Gameiro-Paris

    Dr. Helen Nadel (Stanford, past president of SNMMI) explains what slows the use of targeted radionuclide therapy in children and why she believes adolescents aged 12 and over should be included in theranostics trials.

  • A South African trial explores a new approach to high-risk neuroblastoma in children by Prof. Dr. Jaques Van Heerden & Dr. Anita Brink

    The LuDO-SA trial tests whether adding a single dose of Lutetium-177 DOTATATE to first-line chemotherapy improves early response.

  • Who will deliver the therapy?

    “The constraint on radiopharmaceutical therapy may soon be neither reactors nor isotopes, but people. And when the workforce falls short, it is patients who wait.”

     

    The Human Capital Gap in Targeted Radionuclide Therapy (TRT) Commercialization

    by Taylor Prejna

  • Lasting access: RLT-Connect in Egypt, Kenya and Ghana

    by Dr. Alice Viana & Elisa Cannarozzo

    RLT-Connect, the Oncidium foundation’s treatment donation program, is making the case for equitable access to targeted radionuclide therapy (TRT) heard well beyond the hospitals it supports.

     

  • Targeted Radionuclide Therapy (TRT) Snapsho

    • Radiotheranostics in Kenya: An Emerging Landscape

      by Dr. Elizabeth Itotia

  • NETRF: Accelerating the Next Generation of Neuroendocrine Cancer Research

    Founded by a patient in 2005, the Neuroendocrine Tumor Research Foundation (NETRF) was established with a mission to fund research that leads to cures and more effective treatments for neuroendocrine cancer.

     

  • Lu-177-PSMA-617 from a patient’s perspective

    Dirk Wyndaele, M.D., a nuclear medicine physician affiliated with the new patient advocacy and policy department at the Oncidium foundation, is also living with prostate cancer though he has not received this therapy himself.

  • What's up Oncidium? 
    • Launch of a Patient Advocacy & Policy department

    • The Tackle Cancer Challenge 2026 - 32 additional doses donated

    • Ambassador Meetings - in the U.S.A. & Global

    • Events around the world

    • Consolidating our partnership with the IAEA

    • The 3rd Edition of the Radiotheranostics Summit

    • ICRT: Radiotheranostics Without Borders

    • Nuclear Olympiad: Hackapower LATAM 2026 Successfully Completes Its Final Stage